Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Follow the Journey
Companies On The Road
Arcadis DPS Group
C2 Pharma
CAI
EcoLab
Environmental Systems Corporation
Federal Equipment Company
Globyz Biopharma Services
Grifols
Integrity
Nu-Tek BioSciences
PHARMALEX
Waters Corporation
Follow the Journey
Companies On The Road
ABS
aCGT Vector
Alconox Inc.
Andelyn Biosciences
Arranta Bio
Avid Bioservices
BDD
BIOVECTRA
DPS Group
Dynamk Capital
Environmental Systems Corporation
Federal Equipment Company
Genesis AEC
Globyz Biopharma Services
Grifols Partnership
IDT Biologika
Inceptor Bio
IPS-Integrated Project Services
Kineticos Life Sciences
MilliporeSigma
Montana BioScience Alliance
Olon
Rentschler Biopharma
SanaClis
Scorpion Biological Services
Secant Group
Tapemark
VITRONIC
Follow the Journey
Companies On The Road
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
Nice Insight Reports
2022 Sterile
2023 Cell & Gene Therapy
2023 mAb and Recombinant Protein
2024 API
2024 OSD
2024 ADC
2024 mRNA
2024 Mammalian Cell Culture
2024 Microbial Cell Culture
2024 Plasmids
2024 Gene Therapy
2024 Cell Therapy
2024 Sterile
Community
Company A to Z
Follow the Journey
Companies On The Road
Follow The Artist
Follow the Journey
Companies On The Road
More+
Staffing
Media Kit
Bristol-Myers Squibb
25 Articles Available
0
2
Can't find what you're looking for? Try our
advanced search
.
FDA Approval
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Zeposia® (ozanimod), an Oral Treatment for Adults with Moderately to Severely Active Ulcerative Colitis
PR-M06-21-008
Collaboration
Dragonfly Therapeutics and Bristol Myers Squibb Announce Exclusive Global License for Dragonfly’s IL-12 Investigational Immunotherapy Program
PR-M08-20-NI-35
Diversity
Bristol Myers Squibb and the Bristol Myers Squibb Foundation Commit $300 Million to Accelerate and Expand Health Equity and Diversity and Inclusion Efforts
PR-M08-20-NI-20
FDA
FDA Accepts for Priority Review Bristol Myers Squibb’s Application for CC-486 for Maintenance Treatment of Adult Patients in Remission with Acute Myeloid Leukemia
PR-M05-20-NI-012
Healthcare
Bristol Myers Squibb Expands Patient Support Programs to Help Newly Uninsured Patients in the U.S.
PR-M04-20-NI-010
Digital Therapeutics
Voluntis and Bristol-Myers Squibb to Co-Develop Digital Therapeutics for Oncology
PR-M03-20-NI-011
Collaboration
Evotec and Bristol-Myers Squibb Expand iPSC Collaboration
PR-M01-20-NI-018
Bristol-Myers Squibb Announces Update for Patients with Resected High-Risk Melanoma and PD-L1 <1%
Collaboration
Presage Announces Collaboration with Bristol-Myers Squibb for Phase O Studies of Novel Cancer Agents Utilizing CIVO™ Technology
PR-M09-19-NI-002
M&A
Bristol-Myers Squibb Provides Update on Pending Merger with Celgene
PR-M06-19-NI-051
M&A
BMS–Celgene Merger Still On
PAO-M05-19-NI-007
M&A
Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company
PR-M01-19-NI-017
Oncology
Bristol-Myers Squibb and Infinity Pharmaceuticals Announce a New Clinical Collaboration to Evaluate Opdivo (Nivolumab) in Combination with IPI-549 in Urothelial Cancer
PR-M11-18-NI-029
FDA Approval
U.S. Food and Drug Administration Approves Opdivo®(nivolumab) as the First New Medication in Nearly 20 Years for Certain Patients with Previously Treated Small Cell Lung Cancer
PR-M09-18-NI-065
Funding
IFM Gets Funding to Support Work on NLRP3 Inhibitors
PAO-M07-18-NI-016
U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab)
PR-M04-18-NI-85
Cardiovascular
Janssen Announces Worldwide Development and Commercialization Collaboration with Bristol-Myers Squibb to Advance a Next-Generation Therapy for Cardiovascular Diseases
PR-M04-18-NI-72
Collaboration
Bristol-Myers Squibb and Illumina Announce Strategic Collaboration to Develop and Commercialize Companion Diagnostics
PR-M04-18-NI-64
Oncology
Opdivo (nivolumab), First PD-1 Inhibitor to Demonstrate Superior Survival Benefit Compared with Chemotherapy
PR-M04-18-NI-65
Strategic Collaboration
Bristol-Myers Squibb and Nektar Therapeutics Announce Global Development & Commercialization Collaboration for Nektar’s CD122-biased Agonist, NKTR-214
PR-M02-18-NI-73
Strategic Collaboration
Sirenas Enters Into Multi-Target Collaboration With Bristol-Myers Squibb
PR-M02-18-NI-55
Immuno-Oncology
European Commission Approves Bristol-Myers Squibb’s Yervoy (ipilimumab) for Treatment of Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma
PR-M01-18-NI-082
Innovation
Post-Approval Studies Confirm Therapeutic Value of Oral Anticoagulants
PAO-M09-17-NI-005
Oncology
Bristol-Myers Squibb Will Acquire IFM Therapeutics’ Innate Immune System Stimulators
PAO-M08-17-NI-015
«
0
2
»